Natco Pharma Intrinsic Value
Natco Pharma (NATCOPHARM) median intrinsic value is ₹1842.90 from 9 valuation models (range ₹383–₹2304), vs current price ₹921.45 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit Natco Pharma screener.
NATCOPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Natco Pharma intrinsic value across 9 models vs current price ₹921.45 — upside/downside and value range per method. Analyse NATCOPHARM promoter holding to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1316.48 | ₹1053.18 - ₹1579.78 | +42.9% | EPS: ₹59.84, Sector P/E: 22x |
| Book Value Method | asset | ₹2303.62 | ₹2073.26 - ₹2533.98 | +150.0% | Book Value/Share: ₹2561.39, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1815.56 | ₹1634.00 - ₹1997.12 | +97.0% | Revenue/Share: ₹907.78, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1842.90 | ₹1658.61 - ₹2027.19 | +100.0% | EBITDA: ₹820.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2303.62 | ₹1842.90 - ₹2764.34 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹382.98 | ₹344.68 - ₹421.28 | -58.4% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹924.53 | ₹832.08 - ₹1016.98 | +0.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1842.90 | ₹1658.61 - ₹2027.19 | +100.0% | ROE: 11.7%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1857.06 | ₹1671.35 - ₹2042.77 | +101.5% | EPS: ₹59.84, BVPS: ₹2561.39 |
NATCOPHARM Intrinsic Value vs Market Price — All Valuation Models
Natco Pharma fair value range ₹383–₹2304 vs current market price ₹921.45 across 9 valuation models. Read NATCOPHARM dividend history for the complete payout history and dividend yield track record.
NATCOPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Natco Pharma median intrinsic value ₹1842.90, current price ₹921.45 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of NATCOPHARM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Natco Pharma (NATCOPHARM) is ₹1842.90 (median value). With the current market price of ₹921.45, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹382.98 to ₹2303.62, indicating ₹382.98 - ₹2303.62.
Is NATCOPHARM undervalued or overvalued?
Based on our multi-method analysis, Natco Pharma (NATCOPHARM) appears to be trading below calculated value by approximately 100.0%.
NATCOPHARM Financial Health — Key Ratios vs Industry Benchmarks
Natco Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 29.37 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 11.7% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.30x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
NATCOPHARM Cash Flow Quality — Operating & Free Cash Flow
Natco Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,697 Cr | ₹979 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,212 Cr | ₹699 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹849 Cr | ₹617 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹47 Cr | ₹47 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹299 Cr | ₹246 Cr | Positive Free Cash Flow | 8/10 |